Diagnostic Center of Excellence Team

Driving change in nephrology: PARASOL project leads to FDA acceptance of proteinuria

Designing the Future of Pediatric Rare Disease Trials for Cell and Gene Therapy

Bridging Innovation and Impact: Why Evidence Generation is the New Currency in Biotech

Discover how biotech companies strategically leverage medical evidence generation to demonstrate value, accelerate market access, and drive real-world impact.

Peter M. Neupert

Peter Neupert serves as Fortrea’s Chairman and Interim Chief Executive Officer.

Sustainability in Clinical Trials

Dana Annunziato

Dana has more than 25 years of experience in the pharmaceutical and CRO industry, with 9 years at Fortrea.

How assumptions in protocol design are a root of trial failure: Avoiding “unicorns” in clinical trial protocol design

Accelerate your success with Fortrea’s Site Support Services